Security Snapshot

Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) Institutional Ownership

CUSIP: 98422T100

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

37

Shares (Excl. Options)

39,727,815

Price

$0.64

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
XLO on Nasdaq
Shares outstanding
73,644,024
Price per share
$0.51
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
39,727,815
Total reported value
$25,433,377
% of total 13F portfolios
0%
Share change
+17,967,980
Value change
+$11,324,174
Number of holders
37
Price from insider filings
$0.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 98422T100.
  • 37 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 36 to 37 between Q3 2025 and Q4 2025.
  • Reported value moved from $18,613,906 to $25,433,377.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 37 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 20% 0% $9,581,667 +$2,576,464 14,517,678 +37% GILEAD SCIENCES, INC. 31 Dec 2025
Point72 Asset Management, L.P. 9.9% +39% $6,743,200 +$3,371,600 8,000,000 +100% Point72 Asset Management, L.P. 30 Sep 2025
Bain Capital Life Sciences Fund II, L.P. 8.5% $4,131,430 6,259,742 BCLS II Equity Opportunities, LP 31 Dec 2025
STEMPOINT CAPITAL LP 8.4% +17% $3,979,818 +$1,339,818 6,030,028 +51% StemPoint Capital LP 31 Dec 2025
Coastlands Capital LP 10% $3,742,248 5,346,069 Coastlands Capital LP 04 Dec 2025
Frazier Life Sciences Public Fund, L.P. 6.7% -32% $3,086,472 -$2,286,600 4,676,472 -43% Frazier Life Sciences Public Fund, L.P. 31 Dec 2025
AbbVie Inc. 9% $3,304,348 4,347,826 AbbVie Inc. 11 Feb 2025

As of 31 Dec 2025, 37 institutional investors reported holding 39,727,815 shares of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO). This represents 54% of the company’s total 73,644,024 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 12% 9,105,451 0% 0.3% $5,829,310
Bain Capital Life Sciences Investors, LLC 10% 7,372,686 +61% 0.36% $4,719,994
Frazier Life Sciences Management, L.P. 8% 5,915,091 0.1% $3,786,841
Point72 Asset Management, L.P. 5.4% 4,000,000 0% $2,560,800
Sio Capital Management, LLC 2.9% 2,134,537 0.23% $1,366,531
STEMPOINT CAPITAL LP 2.8% 2,030,028 0.22% $1,299,624
Merck & Co., Inc. 2% 1,483,758 0% 0.34% $949,902
VANGUARD GROUP INC 1.7% 1,255,692 0% 0% $803,643
Empery Asset Management, LP 1.6% 1,183,040 0% 0.67% $757,382
Ghisallo Capital Management LLC 1.5% 1,113,222 0.03% $712,685
MORGAN STANLEY 1.1% 839,850 -13% 0% $537,672
AJU IB Investment Co., Ltd. 0.91% 667,742 0% 2.3% $427,488
FMR LLC 0.69% 511,820 0% 0% $327,667
CITADEL ADVISORS LLC 0.59% 436,216 0% $279,265
RENAISSANCE TECHNOLOGIES LLC 0.47% 344,416 +68% 0% $220,495
GEODE CAPITAL MANAGEMENT, LLC 0.45% 328,972 0% 0% $210,630
STATE STREET CORP 0.25% 186,390 +14% 0% $119,327
Velan Capital Investment Management LP 0.23% 170,000 0.06% $108,834
GSA CAPITAL PARTNERS LLP 0.2% 147,966 0.01% $95,000
Stonepine Capital Management, LLC 0.17% 126,270 0.06% $80,838
NORTHERN TRUST CORP 0.09% 66,609 0% 0% $42,643
TWO SIGMA INVESTMENTS, LP 0.08% 62,032 -29% 0% $39,713
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.08% 56,081 0% 0% $35,903
JANE STREET GROUP, LLC 0.06% 42,080 0% $26,940
HRT FINANCIAL LP 0.04% 31,886 +29% 0% $20,000

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 39,727,815 $25,433,377 +$11,324,174 $0.64 37
2025 Q3 22,051,916 $18,613,906 -$1,227,318 $0.84 36
2025 Q2 23,795,263 $16,179,092 +$854,217 $0.68 35
2025 Q1 22,528,206 $16,318,555 -$3,181,066 $0.72 35
2024 Q4 25,814,355 $24,660,128 -$144,644 $0.96 34
2024 Q3 15,911,945 $12,534,583 +$1,128,156 $0.79 32
2024 Q2 14,508,823 $13,746,216 +$1,785,264 $0.95 31
2024 Q1 12,460,895 $13,460,257 -$2,676,053 $1.08 30
2023 Q4 16,426,281 $9,034,716 -$1,543,598 $0.55 33
2023 Q3 15,860,160 $33,465,952 -$314,935 $2.11 30
2023 Q2 16,002,286 $41,925,598 -$192,245 $2.62 32
2023 Q1 16,072,057 $50,979,505 +$461,644 $3.17 32
2022 Q4 15,926,513 $42,841,966 -$709,927 $2.69 28
2022 Q3 16,606,568 $48,328,000 -$3,750,524 $2.91 28
2022 Q2 17,880,380 $52,211,910 -$3,647,986 $2.92 29
2022 Q1 18,775,939 $132,746,000 -$2,569,332 $7.07 41
2021 Q4 18,324,586 $269,421,063 +$225,248,000 $16.00 41

Sponsored